Wilbur D Scott, Chyan Ming-Kuan, Hamlin Donald K, Kegley Brian B, Risler Reudi, Pathare Pradip M, Quinn Janna, Vessella Robert L, Foulon Catherine, Zalutsky Michael, Wedge Timothy J, Hawthorne M Frederick
Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, USA.
Bioconjug Chem. 2004 Jan-Feb;15(1):203-23. doi: 10.1021/bc034175k.
An investigation has been conducted to assess the in vivo stability of a series of astatinated benzamides and astatinated nido-carborane compounds in mice. It was hypothesized that the higher bond strength of boron-astatine bonds in the nido-carboranes might provide increased stability toward in vivo deastatination. Four tri-n-butylstannylbenzamides were prepared for radiohalogenation and evaluation in vivo. Those compounds were N-propyl-4-(tri-n-butylstannyl)benzamide 1a, N-propyl-3-(tri-n-butylstannyl)benzamide 2a, ethyl 4-tri-n-butylstannylhippurate 3a, and 4-tri-n-butylstannyl-hippuric acid 4a. Seven mono-nido-carboranyl derivatives were prepared for radiohalogenation and in vivo evaluation. Four of the seven mono-carboranyl derivatives (5a, 6a, 7a, 13a) contained a 3-(nido-carboranyl)propionamide functionality, and the remaining compounds (8a, 8g, 10a) contained a 4-(nido-carboranyl)aniline functionality. Two additional derivatives (11a, 12a) were prepared that contained bis-(nido-carboranylmethyl)benzene moieties (also referred to as Venus flytrap complexes (VFCs). All benzamide and nido-carborane compounds underwent facile iodination and radiohalogenation, except a 4-(nido-carboranyl)aniline derivative, 8a. Iodination of 8a resulted in a mixture, of which the desired iodinated product was a minor component. Therefore, radiohalogenation was not attempted. It is believed that the mixture of products is due to the presence of a thiourea bond. Previous studies have shown that thiourea bonds can interfere with halogenation reactions. In vivo comparisons of the compounds were conducted by co-injection of dual labeled (125/131I and 211At) compounds. Tissue distribution data were obtained at 1 and 4 h postinjection of the radiolabeled compounds, as that was sufficient to determine if astatine was being released. Stability of the astatinated compound was assessed by the difference in concentration of radioiodine and astatine in lung and spleen. All of the benzamides were found to undergo rapid deastatination in vivo. The nido-carborane derivatives appeared to be slightly more stable to in vivo deastatination; however, they had long blood residence times. The surprising finding was that the VFC derivatives did not release 211At in vivo, even though they rapidly localized to liver. This finding provides encouragement that stable conjugates of 211At may be attained if appropriate modifications of the VFC can be made to redirect their excretion through the renal system.
已开展一项研究,以评估一系列砹化苯甲酰胺和砹化巢式碳硼烷化合物在小鼠体内的稳定性。据推测,巢式碳硼烷中硼 - 砹键的较高键强度可能使其在体内脱砹过程中具有更高的稳定性。制备了四种三正丁基锡苯甲酰胺用于放射性卤化及体内评估。这些化合物分别是N - 丙基 - 4 -(三正丁基锡基)苯甲酰胺1a、N - 丙基 - 3 -(三正丁基锡基)苯甲酰胺2a、乙基4 - 三正丁基锡马尿酸酯3a和4 - 三正丁基锡马尿酸4a。制备了七种单巢式碳硼烷基衍生物用于放射性卤化及体内评估。七种单碳硼烷基衍生物中的四种(5a、6a、7a、13a)含有3 -(巢式碳硼烷基)丙酰胺官能团,其余化合物(8a、8g、10a)含有4 -(巢式碳硼烷基)苯胺官能团。还制备了另外两种衍生物(11a、12a),它们含有双(巢式碳硼烷甲基)苯部分(也称为捕蝇草络合物(VFCs))。除了一种4 -(巢式碳硼烷基)苯胺衍生物8a外,所有苯甲酰胺和巢式碳硼烷化合物都能顺利进行碘化和放射性卤化。8a的碘化产生了一种混合物,其中所需的碘化产物是次要成分。因此,未尝试进行放射性卤化。据信产物混合物是由于存在硫脲键。先前的研究表明硫脲键会干扰卤化反应。通过共同注射双标记(125/131I和211At)化合物对这些化合物进行体内比较。在注射放射性标记化合物后1小时和4小时获取组织分布数据,因为这足以确定砹是否正在释放。通过肺和脾中放射性碘和砹浓度的差异来评估砹化化合物的稳定性。发现所有苯甲酰胺在体内都会迅速发生脱砹。巢式碳硼烷衍生物在体内脱砹方面似乎稍稳定一些;然而,它们在血液中的停留时间较长。令人惊讶的发现是,VFC衍生物在体内不会释放211At,尽管它们会迅速定位于肝脏。这一发现为以下方面提供了鼓舞:如果能够对VFC进行适当修饰以使其通过肾脏系统重新排泄,可能会获得稳定的211At缀合物。